top of page

Astragalus During Cancer Immunotherapy: A Mouse Study Found the Herb Weakened the Treatment

Writer: Joyce Knieff, NMD, LAc
Joyce Knieff, NMD, LAc
Nov 4
4 min read

Astragalus root has a long history in Chinese medicine, and a lot of people take it to "support the immune system." Given that reputation, a new study from Shanghai is unsettling. In mice with melanoma, a compound extracted from the root made a common type of cancer immunotherapy work less well.


Dried astragalus root slices on a wooden plate
Photo: 本草圈 / Unsplash

What the astragalus and anti-PD-1 study found


The treatment in question is anti-PD-1 therapy, one of the drugs known as immune checkpoint inhibitors. Cancer cells can switch off the immune cells that would otherwise attack them, and these drugs block that switch-off signal so the immune cells can attack the tumor.


Researchers at Fudan University's Huashan Hospital gave mice with melanoma either anti-PD-1 therapy alone or anti-PD-1 combined with astragalus polysaccharide, a sugar-based compound extracted from the root [1]. The researchers described the result as unexpected. Adding the astragalus compound significantly reduced how well the immunotherapy controlled the tumors. Inside the tumors, it reversed the increase in key immune cells that anti-PD-1 had produced, and it interfered with dendritic cells, the cells that show pieces of the tumor to the rest of the immune system so it knows what to attack [1]. The team traced this to two signaling pathways that the immune response depends on.


This was a mouse study. According to the news coverage of the paper, it used 24 mice split into four groups [1]. In the paper, the authors concluded that combining natural polysaccharides with checkpoint inhibitors "may warrant caution," and they called for more studies to confirm the findings and to work out their relevance to people [1].


What other astragalus studies have found


The same research group reported a similar result in 2025, using an astragalus injection given to melanoma-bearing mice alongside anti-PD-1 [2]. The astragalus product again reduced the drug's effect and lowered immune cell infiltration into the tumors. That makes two results showing the same effect, although both studies came from one lab using the same type of mouse model.


Other mouse studies have reported the opposite. An isolated astragalus compound called astragaloside IV made anti-PD-1 work better in mice with prostate cancer [3]. In mice with triple-negative breast cancer, a gel made from astragalus polysaccharide and loaded with a second plant compound improved the effect of a related checkpoint drug [4]. A 2022 review of laboratory research found that astragalus polysaccharide usually increases the activity of many immune cell types [5], which is part of why the new result surprised the researchers.


I could not find any study of this combination in people. Patients on these drugs already use herbs and supplements, though. A 2024 survey of 181 patients receiving checkpoint inhibitors found that about 9 percent used herbal medicines and about 24 percent used dietary supplements during treatment [6]. Boosting the immune system was the most common reason. Most of their information came from family members and TV advertisements, with limited advice from healthcare professionals [6].


Why "immune support" is the wrong way to think about herbs during cancer treatment


Results like this are the reason I avoid describing any herb as simply "immune boosting." The immune system has signals that increase its activity and signals that reduce it, and the cells involved respond differently depending on what else is going on in the body. A compound that increases immune activity in one setting can interfere with a drug that depends on a very specific immune response in another, and the mouse studies above found weaker immunotherapy results in some experiments and stronger results in others, depending on the astragalus compound, the type of cancer, and how it was given.


Herbs are pharmacologically active. That is the reason they can help, and it is also the reason they can interact with other treatments. For someone in active cancer treatment, integrative care means the naturopathic doctor and the oncology team work together, so that they choose every herb and supplement with the full treatment plan in view.


Should you take astragalus during cancer immunotherapy?


No one can answer that from mouse data, and it is a decision for you and your oncology team together.


  1. A complete list for your oncologist. If you are receiving or about to start immunotherapy, tell your oncology team about every herb, tea, tincture, and supplement you take, including combination formulas where astragalus may be one ingredient among many.

  2. Questions before changes. If you are already taking astragalus, ask your oncology team before stopping or continuing it, rather than making the change on your own based on one study.

  3. A naturopathic doctor who works with your oncologist. If you want integrative support during treatment, look for a practitioner who will coordinate directly with your oncology team.

  4. Healthy skepticism about "immune boosting" claims. You cannot learn from immune-support marketing how a product interacts with cancer drugs.


References


  1. Wang R, Li Q, Liu M, et al. Astragalus polysaccharide antagonized anti PD-1 efficacy in melanoma through inhibiting JAK-STAT1/CIITA and TLR/NF-κB signaling. Front Immunol. 2026;17:1947786. PMID 42807196. doi:10.3389/fimmu.2026.1947786. Original news coverage (AANP digest): https://www.sciencealert.com/a-common-herbal-supplement-may-interfere-with-cancer-treatment-study-suggests

  2. Lei R, Li Q, Wang R, et al. Astragalus injection antagonizes the efficacy of anti-PD-1 against melanoma through down-regulating MHC-II expression. J Ethnopharmacol. 2025;349:119966. PMID 40354837. doi:10.1016/j.jep.2025.119966

  3. Yang J, Wang J, Zhang W, et al. Astragaloside IV directly targets PPP1R14B to sensitize prostate cancer to anti-PD-1 immunotherapy by remodeling the CX3CL1/CD8T cell axis. Phytomedicine. 2026;155:158158. PMID 41950731. doi:10.1016/j.phymed.2026.158158

  4. Ma A, Wang G, Shen M, et al. Astragalus polysaccharide-based thermoresponsive hydrogel loaded with β-elemene nanoemulsion in combination with anti-PD-L1 therapy for triple-negative breast cancer. Int J Biol Macromol. 2026;375:153414. PMID 42419545. doi:10.1016/j.ijbiomac.2026.153414

  5. Li CX, Liu Y, Zhang YZ, Li JC, Lai J. Astragalus polysaccharide: a review of its immunomodulatory effect. Arch Pharm Res. 2022;45(6):367-389. PMID 35713852. doi:10.1007/s12272-022-01393-3 (Yggdrasil abstract library)

  6. Kus F, Can Guven D, Yildirim HC, et al. The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study. Integr Cancer Ther. 2024;23:15347354241280273. PMID 39367737. doi:10.1177/15347354241280273


This post is for education only and is not medical advice. If you have cancer or are receiving cancer treatment, please make any decisions about herbs, supplements, or medications together with your oncology team.



If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.




 
 
 

Comments


bottom of page